Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/09546634.2020.1775774 http://scihub22266oqcxt.onion/10.1080/09546634.2020.1775774 32459567!ä!32459567 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32459567.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Dermatolog+Treat 2022 ; 33 (2): 622-625 Nephropedia Template TP {{tp|p=32459567|t=2022. Use of systemic therapies for psoriasis in the COVID-19 era |pdf=|usr=}}{{32459567}} gab.com Text Use of systemic therapies for psoriasis in the COVID-19 era JO: J Dermatolog Treat http://www.kidney.de/pget.php?&tw=1&pmid=32459567 #FOAvip BACKGROUND: In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis. OBJECTIVE: The purpose of this review is to analyze what is currently known about COVID-19 in regard to the safety of systemic treatment, and to provide guidelines for use in psoriasis during this pandemic. METHODS: Review of guidelines from various dermatologic regulatory bodies regarding the use of systemic medications during the COVID-19 pandemic was performed and summarized. RESULTS: The AAD, NPF and IPC are in agreement regarding their recommendation that patients with active COVID-19 infection should discontinue any biologic therapy. CONCLUSION: Patients with active COVID-19 infections should discontinue systemic treatment for psoriasis. Patients with risk factors should discuss continuing treatment on a case by case basis. Twit Text FOAVip Use of systemic therapies for psoriasis in the COVID-19 era ????J Dermatolog Treat http://www.kidney.de/pget.php?&tw=1&pmid=32459567 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32459567 #FOAvip English Wikipedia <ref>{{Cite pmid|32459567}}</ref> Use of systemic therapies for psoriasis in the COVID-19 era #MMPMID32459567 Kearns DG; Uppal S; Chat VS; Wu JJ J Dermatolog Treat 2022[Mar]; 33 (2): 622-625 PMID32459567show ga BACKGROUND: In late 2019 a viral pneumonia began to spread across the world. The viral disease, COVID-19, is now officially a pandemic, causing concern for the potential risk of systemic therapies for patients with psoriasis. OBJECTIVE: The purpose of this review is to analyze what is currently known about COVID-19 in regard to the safety of systemic treatment, and to provide guidelines for use in psoriasis during this pandemic. METHODS: Review of guidelines from various dermatologic regulatory bodies regarding the use of systemic medications during the COVID-19 pandemic was performed and summarized. RESULTS: The AAD, NPF and IPC are in agreement regarding their recommendation that patients with active COVID-19 infection should discontinue any biologic therapy. CONCLUSION: Patients with active COVID-19 infections should discontinue systemic treatment for psoriasis. Patients with risk factors should discuss continuing treatment on a case by case basis. |*COVID-19[MESH] |*Pneumonia, Viral/epidemiology[MESH] |*Psoriasis/complications/drug therapy/epidemiology[MESH] |Humans[MESH]Use of systemic therapies for psoriasis in the COVID-19 era (epmc).pdf DeepDyve Pubget Overpricing